The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO Asia 2025 | How can clinicians incorporate peri-operative treatment in lung cancer?
Jazmin Eckhaus, MBBS, FRACS, St Vincent’s Hospital, Melbourne, Australia, discusses the importance of incorporating neoadjuvant care for patients with lung cancer, focusing on institutional practice changes and individual clinician efforts to facilitate completion of treatment. A clear patient understanding of the treatment course is needed, including all steps involved, and meeting with the surgeon before starting treatment can help ensure patients are well-informed and prepared. This interview took place at 2025 European Society for Medical Oncology (ESMO) Asia Congress in Singapore, Singapore.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Although I’m a surgeon, my talk really focused on the practical side of how you can start incorporating new adjuvant care for your patients with lung cancer. So I talked a little bit about the operative details, but the focus of my talk was really around institutional practice changes and other things that individual clinicians can do to get patients over the line so that they can receive both chemotherapy and immunotherapy and then a surgical procedure...
Although I’m a surgeon, my talk really focused on the practical side of how you can start incorporating new adjuvant care for your patients with lung cancer. So I talked a little bit about the operative details, but the focus of my talk was really around institutional practice changes and other things that individual clinicians can do to get patients over the line so that they can receive both chemotherapy and immunotherapy and then a surgical procedure. There’s no one thing that we can do that will definitely get patients across the line. But when you look at the data about why patients fail to complete treatment, excluding the disease factors, what you see is that there’s often either system-level problems or just individual problems. I think one of the most powerful things we can do as clinicians is make sure that patients clearly understand before they start their treatment course all the steps that are involved. And my personal approach is that patients meet the surgeon, usually me in this case, before they start all their treatment. So they understand that the treatment that’s provided by their oncologist is one half and then the next half continues.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
